Natco Pharma fell 1.72% to Rs 610.75 amid profit booking.
The stock jumped 8.31% in six sessions to end at Rs 620.70 yesterday from a recent closing low of Rs 573.05 recorded on 24 December 2019.
Natco Pharma after market hours on Thursday announced submission of an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (USFDA) for the generic version of Lonsurf (Trifluridine/ Tipiracil) tablets (15mg/6.14mg and 20mg/8.19mg). Natco believes that it is one of the first ANDA filers for the product and could be eligible for 180 days exclusivity under certain circumstances.
Lonsurf has recorded sales of $150 million for the year ending December 2018 in the US market as per IQVIA. The drug is currently indicated for certain forms of colorectal and gastric cancers. Lonsurf is a registered trademark of Taiho Oncology, INC.
Natco Pharma is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others.
The company's consolidated net profit fell 35.2% to Rs 117.70 crore on 10.6% decline in net sales to Rs 485.70 crore in Q2 September 2019 over Q2 September 2018.
On the technical front, the stock's RSI (relative strength index) stood at 64.39. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.
More From This Section
The stock was currently trading above its 50-day moving average (DMA) placed at Rs 580, as well as above its 200 DMA placed at Rs 555.05.
Powered by Capital Market - Live News